AspireAssist device
Jump to navigation
Jump to search
Indications
* more effective than counseling alone[2]
Adverse effects
- common
- peristomal granulation tissue
- non-specific abdominal pain
- dyspepsia
- serious
- peritonitis
- peptic ulcer
- tube malfunction[2]
Procedure
- endoscopic insertion of a tube into the stomach via a small incision in the abdomen
- a disk-shaped port valve that lies outside the body, flush against the skin of the abdomen, is connected to the tube & remains in place
- ~20-30 minutes after meal consumption, an external connector & tubing is attached to the port valve
- the port valve is opened & the contents drained into a toilet - this takes ~5-10 minutes[1]
Mechanism of action
- surgically-placed tube to drain a portion of the stomach contents after every meal
- BMI reduction of ~12% after 1 year[1]
More general terms
References
- ↑ 1.0 1.1 1.2 1.3 FDA News Release. June 14, 2016 FDA approves AspireAssist obesity device. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm506625.htm
- ↑ 2.0 2.1 2.2 2.3 2.4 Thompson CC, Abu Dayyeh BK Kushner R et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: Results of a randomized controlled trial. Am J Gastroenterol 2017 Mar; 112:447 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27922026